Russian Export Center acted as BIOTECHMED 2018 general partner
Russia's key biomedical technologies forum BIOTECHMED 2018 held in Gelendzhik with the Russian Export Center acting as the general partner of the event.
Russia's pharmaceutical industry main problem is complexity and high costs of testing on foreign markets in order to obtain international certificates which would allow exporting the products.”
MOSCOW, RUSSIA, September 18, 2018 /EINPresswire.com/ -- Russia's key biomedical technologies forum BIOTECHMED 2018 was held in Gelendzhik on September, 9-11 with the Russian Export Center acting as the general partner of the event.— Irina Kashirina, Head of medical and pharmaceutical project, REC
Medical services and devices export was one of BIOTECHMED 2018 key topics. During the forum its participants discussed the questions of Russia's pharmaceutical, biotechnological, medical and cosmetics industry enterprises development and realization of their potential.
REC, being the state-owned development institution, acted as an expert during the forum's programme, occupied a separate pavilion at the exhibition and hosted a press conference. The Center specialists shared the information on the existing export cycle, entrepreneurial activities in exports and external economic activity.
According to the Edict of the President of the Russian Federation Vladimir Putin, the Russian enterprises should double the non-resource non-energy export volumes during the next six years. During the Forum REC organized a series of events and meetings dedicated to the questions of the Russian medicine and medical services export.
On September, 10 Irina Kashirina, REC Head of the medical and pharmaceutical industry export support project spoke during the panel "Export cooperation development in biotechnology and biomedicine". The participants discussed export development measures in the context of cooperation among Russia's Minpromtorg, REC and the manufacturers, taking into account successful cases.
Irina Kashirina also took part in the panel "The strategy of Russia's cosmetics industry development". The session included discussion of R&D competences development as well as export potential of Russia's cosmetics industry.
BIOTECHMED forum also included a press conference with Irina Kashirina, REC Head of the medical and pharmaceutical industry export support project. The press conference touched upon the plan on Russia's medical and pharmaceutical industry export support measures that are to enter the national project "International cooperation and exports" and will allow reaching the targeted indicators designated by Russia's President Vladimir Putin.
"Russia's pharmaceutical industry main problem is complexity and high costs of testing on foreign markets in order to obtain international certificates which would allow exporting the products. We are now preparing a set of norms that will allow the companies to more effectively use the financial support measures to pass these tests", Irina Kashirina, REC Head of the medical and pharmaceutical industry export support project said.
REC occupied a separate pavilion at the exhibition, which acted as a venue for talks and meetings between foreign buyers and exhibitors.
"I'm sure that hosting such forums like BIOTECHMED with REC acting as the general partner will also help to raise interest in our country – it is critical to openly discuss with all the stakeholders the future development of this direction, which is crucial for the economy", said Andrey Slepnev, REC General Director while summarizing the forum results.
More than 1,500 experts from 52 regions and more than 300 companies took part in BIOTECHMED 2017 forum. JSC National Immunobiological Company; JSC Schwabe; LLC NCI; JSC POZiS; JSC Pharmasintez; Skolkovo Foundation; OOO MERK; ZAO BIOCAD; Russian Helicopters; NP Biotechnology of the Future; Novaya Meditsina LLC (DOC +); Marathon Pharma; Konversiya NPO; NIPK Elektron; NPP Pharmaclon; ChemRar; ELTA Company and GRPZ became BIOTECHMED forum partners.
Irina Gatilova
BIOTECHMED
+7 925 997 25 47
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
